COMP <GO>
EWTX vs ABCL // NET PROFIT MARGIN
Edgewise Therapeutics Inc. (NASDAQ) VS. AbCellera Biologics Inc. (NASDAQ) • 15-METRIC TALLY: EWTX 5
— ABCL 4
▲ NET PROFIT MARGIN LEADER: EWTX
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
net-margins
0.00%
LAST: $11.12 (-9.37%) • MKT CAP: $3.97B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. ABCL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | ABCL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | -20.50% | -11.40 | ABCL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | -4.11% | +0.70 | EWTX | /fcf-yield <GO> |
| Operating Margin | -16.20% | -60.00% | +43.80 | EWTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | -60.00% | +60.00 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 160.60% | -161.70 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.60 | +19.40 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | ABCL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 49.0 | -3.30 | ABCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $3.97B | $250.4M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | ABCL REV | EWTX GROSS % | ABCL GROSS % | EWTX FCF | ABCL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $535.9M | $75.1M | — | — | -$144.1M | -$174.1M |
| FY 2024 | $444.7M | $28.8M | — | — | -$110.3M | -$187.0M |
| FY 2023 | $320.2M | $38.0M | — | — | -$91.9M | -$43.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
ABCL // BETA —